Načítá se...
Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...
Uloženo v:
| Vydáno v: | Drug Des Devel Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://ncbi.nlm.nih.gov/pubmed/28243060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S125459 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|